Financhill
Buy
57

NVSEF Quote, Financials, Valuation and Earnings

Last price:
$107.54
Seasonality move :
4.92%
Day range:
$107.54 - $107.54
52-week range:
$94.70 - $123.55
Dividend yield:
3.78%
P/E ratio:
16.46x
P/S ratio:
3.98x
P/B ratio:
5.41x
Volume:
244
Avg. volume:
77.5K
1-year change:
11.23%
Market cap:
$207.7B
Revenue:
$51.7B
EPS (TTM):
$6.39

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
NVSEF
Novartis AG
$13B -- 8.26% -- --
ALC
Alcon
$2.5B $0.77 4.63% 73.39% $106.65
CRSP
CRISPR Therapeutics AG
$6M -$1.28 -96.36% -7.71% $81.92
RHHBY
Roche Holding AG
$18.9B -- -- -- $46.42
SDZNY
Sandoz Group AG
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
NVSEF
Novartis AG
$105.15 -- $207.7B 16.46x $3.98 3.78% 3.98x
ALC
Alcon
$95.75 $106.65 $47.4B 46.71x $0.26 0.28% 4.81x
CRSP
CRISPR Therapeutics AG
$35.62 $81.92 $3.1B -- $0.00 0% --
RHHBY
Roche Holding AG
$39.11 $46.42 $248.9B 27.25x $1.36 3.49% 3.58x
SDZNY
Sandoz Group AG
$44.90 -- $19.3B 26.84x $0.67 1.5% 1.88x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
NVSEF
Novartis AG
43.44% -0.184 13.67% 0.50x
ALC
Alcon
17.71% 0.592 11.05% 1.72x
CRSP
CRISPR Therapeutics AG
-- 1.979 -- 21.97x
RHHBY
Roche Holding AG
52.17% 0.311 16.91% 1.19x
SDZNY
Sandoz Group AG
35.63% 1.001 25.91% 0.76x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
NVSEF
Novartis AG
$10.4B $4.7B 18.39% 30.96% 34.34% $2.2B
ALC
Alcon
$1.4B $395M 3.97% 4.85% 15.87% $410M
CRSP
CRISPR Therapeutics AG
-$57.5M -$148.4M -18.65% -18.65% -184.54% -$54.2M
RHHBY
Roche Holding AG
-- -- 12.15% 23.8% -- --
SDZNY
Sandoz Group AG
-- -$3.6M -- -- -13.72% --

Novartis AG vs. Competitors

  • Which has Higher Returns NVSEF or ALC?

    Alcon has a net margin of 26.48% compared to Novartis AG's net margin of 11.35%. Novartis AG's return on equity of 30.96% beat Alcon's return on equity of 4.85%.

    Company Gross Margin Earnings Per Share Invested Capital
    NVSEF
    Novartis AG
    76.31% $1.82 $67.9B
    ALC
    Alcon
    55.36% $0.57 $26.2B
  • What do Analysts Say About NVSEF or ALC?

    Novartis AG has a consensus price target of --, signalling downside risk potential of -21.07%. On the other hand Alcon has an analysts' consensus of $106.65 which suggests that it could grow by 11.39%. Given that Alcon has higher upside potential than Novartis AG, analysts believe Alcon is more attractive than Novartis AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    NVSEF
    Novartis AG
    0 0 0
    ALC
    Alcon
    17 3 0
  • Is NVSEF or ALC More Risky?

    Novartis AG has a beta of 0.566, which suggesting that the stock is 43.441% less volatile than S&P 500. In comparison Alcon has a beta of 1.058, suggesting its more volatile than the S&P 500 by 5.816%.

  • Which is a Better Dividend Stock NVSEF or ALC?

    Novartis AG has a quarterly dividend of $3.98 per share corresponding to a yield of 3.78%. Alcon offers a yield of 0.28% to investors and pays a quarterly dividend of $0.26 per share. Novartis AG pays 63.85% of its earnings as a dividend. Alcon pays out 12.77% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NVSEF or ALC?

    Novartis AG quarterly revenues are $13.6B, which are larger than Alcon quarterly revenues of $2.5B. Novartis AG's net income of $3.6B is higher than Alcon's net income of $284M. Notably, Novartis AG's price-to-earnings ratio is 16.46x while Alcon's PE ratio is 46.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 3.98x versus 4.81x for Alcon. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NVSEF
    Novartis AG
    3.98x 16.46x $13.6B $3.6B
    ALC
    Alcon
    4.81x 46.71x $2.5B $284M
  • Which has Higher Returns NVSEF or CRSP?

    CRISPR Therapeutics AG has a net margin of 26.48% compared to Novartis AG's net margin of -106.6%. Novartis AG's return on equity of 30.96% beat CRISPR Therapeutics AG's return on equity of -18.65%.

    Company Gross Margin Earnings Per Share Invested Capital
    NVSEF
    Novartis AG
    76.31% $1.82 $67.9B
    CRSP
    CRISPR Therapeutics AG
    -- -$1.58 $1.9B
  • What do Analysts Say About NVSEF or CRSP?

    Novartis AG has a consensus price target of --, signalling downside risk potential of -21.07%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.92 which suggests that it could grow by 129.97%. Given that CRISPR Therapeutics AG has higher upside potential than Novartis AG, analysts believe CRISPR Therapeutics AG is more attractive than Novartis AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    NVSEF
    Novartis AG
    0 0 0
    CRSP
    CRISPR Therapeutics AG
    12 10 1
  • Is NVSEF or CRSP More Risky?

    Novartis AG has a beta of 0.566, which suggesting that the stock is 43.441% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.877, suggesting its more volatile than the S&P 500 by 87.729%.

  • Which is a Better Dividend Stock NVSEF or CRSP?

    Novartis AG has a quarterly dividend of $3.98 per share corresponding to a yield of 3.78%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novartis AG pays 63.85% of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NVSEF or CRSP?

    Novartis AG quarterly revenues are $13.6B, which are larger than CRISPR Therapeutics AG quarterly revenues of $35M. Novartis AG's net income of $3.6B is higher than CRISPR Therapeutics AG's net income of -$136M. Notably, Novartis AG's price-to-earnings ratio is 16.46x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 3.98x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NVSEF
    Novartis AG
    3.98x 16.46x $13.6B $3.6B
    CRSP
    CRISPR Therapeutics AG
    -- -- $35M -$136M
  • Which has Higher Returns NVSEF or RHHBY?

    Roche Holding AG has a net margin of 26.48% compared to Novartis AG's net margin of --. Novartis AG's return on equity of 30.96% beat Roche Holding AG's return on equity of 23.8%.

    Company Gross Margin Earnings Per Share Invested Capital
    NVSEF
    Novartis AG
    76.31% $1.82 $67.9B
    RHHBY
    Roche Holding AG
    -- -- $78.4B
  • What do Analysts Say About NVSEF or RHHBY?

    Novartis AG has a consensus price target of --, signalling downside risk potential of -21.07%. On the other hand Roche Holding AG has an analysts' consensus of $46.42 which suggests that it could grow by 18.68%. Given that Roche Holding AG has higher upside potential than Novartis AG, analysts believe Roche Holding AG is more attractive than Novartis AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    NVSEF
    Novartis AG
    0 0 0
    RHHBY
    Roche Holding AG
    2 5 0
  • Is NVSEF or RHHBY More Risky?

    Novartis AG has a beta of 0.566, which suggesting that the stock is 43.441% less volatile than S&P 500. In comparison Roche Holding AG has a beta of 0.468, suggesting its less volatile than the S&P 500 by 53.23%.

  • Which is a Better Dividend Stock NVSEF or RHHBY?

    Novartis AG has a quarterly dividend of $3.98 per share corresponding to a yield of 3.78%. Roche Holding AG offers a yield of 3.49% to investors and pays a quarterly dividend of $1.36 per share. Novartis AG pays 63.85% of its earnings as a dividend. Roche Holding AG pays out 92.43% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NVSEF or RHHBY?

    Novartis AG quarterly revenues are $13.6B, which are larger than Roche Holding AG quarterly revenues of --. Novartis AG's net income of $3.6B is higher than Roche Holding AG's net income of --. Notably, Novartis AG's price-to-earnings ratio is 16.46x while Roche Holding AG's PE ratio is 27.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 3.98x versus 3.58x for Roche Holding AG. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NVSEF
    Novartis AG
    3.98x 16.46x $13.6B $3.6B
    RHHBY
    Roche Holding AG
    3.58x 27.25x -- --
  • Which has Higher Returns NVSEF or SDZNY?

    Sandoz Group AG has a net margin of 26.48% compared to Novartis AG's net margin of -39.83%. Novartis AG's return on equity of 30.96% beat Sandoz Group AG's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NVSEF
    Novartis AG
    76.31% $1.82 $67.9B
    SDZNY
    Sandoz Group AG
    -- -$0.28 $12.7B
  • What do Analysts Say About NVSEF or SDZNY?

    Novartis AG has a consensus price target of --, signalling downside risk potential of -21.07%. On the other hand Sandoz Group AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Novartis AG has higher upside potential than Sandoz Group AG, analysts believe Novartis AG is more attractive than Sandoz Group AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    NVSEF
    Novartis AG
    0 0 0
    SDZNY
    Sandoz Group AG
    0 0 0
  • Is NVSEF or SDZNY More Risky?

    Novartis AG has a beta of 0.566, which suggesting that the stock is 43.441% less volatile than S&P 500. In comparison Sandoz Group AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock NVSEF or SDZNY?

    Novartis AG has a quarterly dividend of $3.98 per share corresponding to a yield of 3.78%. Sandoz Group AG offers a yield of 1.5% to investors and pays a quarterly dividend of $0.67 per share. Novartis AG pays 63.85% of its earnings as a dividend. Sandoz Group AG pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NVSEF or SDZNY?

    Novartis AG quarterly revenues are $13.6B, which are larger than Sandoz Group AG quarterly revenues of $74.4M. Novartis AG's net income of $3.6B is higher than Sandoz Group AG's net income of -$29.6M. Notably, Novartis AG's price-to-earnings ratio is 16.46x while Sandoz Group AG's PE ratio is 26.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 3.98x versus 1.88x for Sandoz Group AG. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NVSEF
    Novartis AG
    3.98x 16.46x $13.6B $3.6B
    SDZNY
    Sandoz Group AG
    1.88x 26.84x $74.4M -$29.6M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Spotify a Millionaire-Maker Stock?
Is Spotify a Millionaire-Maker Stock?

Spotify (NYSE:SPOT) may seem like an expensive proposition trading closer…

What Is a Millionaire-Maker Stock?
What Is a Millionaire-Maker Stock?

From time to time, investors will run across the term…

5 Investors to Follow Other Than Warren Buffett
5 Investors to Follow Other Than Warren Buffett

There is no doubt that Warren Buffett is one of…

Stock Ideas

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Buy
63
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 40x

Alerts

Sell
50
QDEL alert for May 10

QuidelOrtho [QDEL] is down 0.22% over the past day.

Buy
97
NGVC alert for May 10

Natural Grocers by Vitamin Cottage [NGVC] is up 30.26% over the past day.

Sell
38
ONTO alert for May 10

Onto Innovation [ONTO] is down 30.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock